These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723 [TBL] [Abstract][Full Text] [Related]
48. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. Huang Y; Carbone DP Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052 [TBL] [Abstract][Full Text] [Related]
49. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647 [TBL] [Abstract][Full Text] [Related]
50. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Zhang L; Takara K; Yamakawa D; Kidoya H; Takakura N Cancer Sci; 2016 Jan; 107(1):36-44. PubMed ID: 26475217 [TBL] [Abstract][Full Text] [Related]
51. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Ellis LM; Rosen L; Gordon MS Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372 [TBL] [Abstract][Full Text] [Related]
52. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Tabernero J Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728 [TBL] [Abstract][Full Text] [Related]
53. A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named "normalization". El Alaoui-Lasmaili K; Djermoune EH; Tylcz JB; Meng D; Plénat F; Thomas N; Faivre B Angiogenesis; 2017 Feb; 20(1):149-162. PubMed ID: 27942994 [TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Maj E; Papiernik D; Wietrzyk J Int J Oncol; 2016 Nov; 49(5):1773-1784. PubMed ID: 27826619 [TBL] [Abstract][Full Text] [Related]
55. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
56. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Ferrara N Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033 [TBL] [Abstract][Full Text] [Related]
57. Antiangiogenic therapy for cancer: current and emerging concepts. Jain RK Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498 [TBL] [Abstract][Full Text] [Related]
58. Vessel pruning or healing: endothelial metabolism as a novel target? Cantelmo AR; Pircher A; Kalucka J; Carmeliet P Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641 [TBL] [Abstract][Full Text] [Related]
59. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Trédan O; Lacroix-Triki M; Guiu S; Mouret-Reynier MA; Barrière J; Bidard FC; Braccini AL; Mir O; Villanueva C; Barthélémy P Target Oncol; 2015 Jun; 10(2):189-98. PubMed ID: 25185646 [TBL] [Abstract][Full Text] [Related]
60. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review). Taurone S; Galli F; Signore A; Agostinelli E; Dierckx RA; Minni A; Pucci M; Artico M Int J Oncol; 2016 Aug; 49(2):437-47. PubMed ID: 27277340 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]